What is the difference between the WHI E-alone and E+P trials?

The E-alone arm tested conjugated equine estrogen by itself in women who had undergone hysterectomy. The E+P arm tested the same estrogen combined with medroxyprogesterone acetate in women with an intact uterus. The combined arm was stopped in 2002 due to increased breast cancer and cardiovascular events. The estrogen-alone arm showed a markedly different, more favorable profile.

Did estrogen alone increase breast cancer risk in the WHI?

No. The original trial showed a non-significant trend toward reduced breast cancer (HR 0.77). Extended follow-up through 2012 confirmed a statistically significant 23% reduction in invasive breast cancer among women randomized to estrogen alone.

Why was the WHI E-alone trial stopped early?

The NIH Data Safety Monitoring Board stopped the trial in February 2004 due to increased stroke risk and an assessment that the global index was unlikely to demonstrate overall benefit. The decision was not driven by heart disease or breast cancer findings.

What dose of estrogen was used in the WHI E-alone trial?

Participants received conjugated equine estrogen (Premarin) at 0.625 mg per day, which was the most commonly prescribed dose at that time. Lower doses and transdermal formulations were not tested.

Does the WHI E-alone trial apply to younger women starting HRT?

Partially. The average age at enrollment was 63, which is older than most women initiating HRT. Age-stratified analyses suggest women aged 50 to 59 had the most favorable outcomes. Subsequent analyses support a timing hypothesis that starting estrogen closer to menopause confers more benefit and less risk.

Did estrogen alone increase stroke risk?

Yes. Stroke risk was significantly elevated (HR 1.39). This was the main safety signal in the trial, amounting to roughly 12 extra strokes per 10,000 person-years. The risk may differ with transdermal estrogen formulations, though the WHI did not test those.

Is conjugated equine estrogen still prescribed today?

Yes. CEE remains FDA-approved for menopausal symptom management and osteoporosis prevention. It is typically prescribed at the lowest effective dose. Transdermal estradiol has grown in popularity as an alternative, but CEE retains the largest long-term evidence base from the WHI.

What did long-term follow-up of the WHI E-alone trial show?

Follow-up through a median of 11.8 years confirmed a statistically significant breast cancer reduction. Cardiovascular outcomes remained neutral overall but trended favorably in younger women. Total mortality was not significantly different between groups.

Should women with a hysterectomy take estrogen?

The WHI E-alone data support estrogen-alone therapy as a reasonable option for symptomatic postmenopausal women with prior hysterectomy, particularly those under 60 or within 10 years of menopause. Individual risk factors, especially stroke risk, should guide the decision. Current guidelines from the Endocrine Society and NAMS support this position.

WHI E-alone Trial: A Plain-English Overview of What It Established

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

Trial name: Women's Health Initiative Estrogen-Alone Trial
N: 10,739 postmenopausal women with prior hysterectomy
Intervention: Conjugated equine estrogen (CEE) 0.625 mg/day
Comparator: Matching placebo
Duration: Planned for 8.5 years; stopped early at a median of 6.8 years
Primary endpoint: Nonfatal myocardial infarction or coronary death (CHD)
Key result: No significant increase in CHD (HR 0.91 to 95% CI 0.75, 1.12); a non-significant reduction in breast cancer (HR 0.77 to 95% CI 0.59, 1.01)

Why This Trial Exists

By 2002, the WHI combined estrogen-plus-progestin arm had already been stopped early because of excess breast cancer and cardiovascular events. That result threw decades of clinical practice into question. But a second arm of the WHI was still running: a parallel trial testing estrogen alone (without progestin) in women who had already had a hysterectomy.

The rationale was straightforward. Progestin is added to HRT only to protect the uterus from endometrial cancer. Women without a uterus do not need it. The estrogen-alone arm was designed to answer whether estrogen by itself carried the same cardiovascular and cancer risks that the combined arm had revealed, or whether progestin was driving those harms.

This distinction matters because millions of women undergo hysterectomy. If estrogen alone had a different risk profile, those women deserved a separate evidence base, not guilt by association with a drug combination they would never take.

Who Was Enrolled

Participants were postmenopausal women aged 50 to 79 who had undergone hysterectomy prior to enrollment. Recruitment took place across 40 U.S. clinical centers between 1993 and 1998. Key inclusion details:

Average age at enrollment: 63.6 years
Roughly 75% were white; 15% were Black
About 48% had used prior hormone therapy
Women with a history of breast cancer were excluded
Women with a predicted survival of fewer than three years were excluded

One important design choice: the trial enrolled women well past menopause onset. The average participant was more than a decade removed from her last menstrual period. This matters because later analyses showed that the age at which estrogen is started changes the risk-benefit balance considerably.

What They Were Given

The intervention was conjugated equine estrogen (CEE) at 0.625 mg per day, the standard clinical dose at the time. The comparator was an identical-looking placebo pill. Neither participants nor investigators knew who received which treatment.

Adherence was tracked through pill counts. By year six, about 54% of the CEE group was still taking the study medication. Drop-in rates (placebo-assigned women starting hormone therapy on their own) were roughly 6%. These adherence gaps are a common challenge in long-duration prevention trials, and they tend to dilute treatment effects toward the null.

What Was Measured

The primary endpoint was nonfatal myocardial infarction or death from coronary heart disease. The primary safety outcome was invasive breast cancer. A global index combined these with stroke, pulmonary embolism, colorectal cancer, hip fracture, and death from other causes to give an overall risk-benefit snapshot.

All cardiovascular events and cancers were adjudicated by blinded committees reviewing medical records, not simply by participant self-report. This is a meaningful quality feature that reduces misclassification.

Results: What the Trial Actually Found

Coronary Heart Disease

The headline finding: estrogen alone did not increase heart disease risk. The hazard ratio was 0.91 (95% CI 0.75 to 1.12). This was a stark contrast to the combined HRT arm, where coronary events increased early in the trial.

Breast Cancer

CEE showed a non-significant reduction in invasive breast cancer (HR 0.77 to 95% CI 0.59 to 1.01). This approached statistical significance and stood in direct opposition to the combined arm, where breast cancer increased by 26%. Extended follow-up data published in The Lancet in 2012 confirmed a statistically significant reduction in breast cancer with estrogen alone over a median 11.8 years of cumulative follow-up (HR 0.77 to 95% CI 0.62, 0.95).

Stroke

Stroke risk was elevated (HR 1.39 to 95% CI 1.10 to 1.77). This was the primary safety signal and one of the reasons the trial was stopped early by the Data Safety Monitoring Board. The excess was about 12 additional strokes per 10,000 person-years.

Hip Fracture

Estrogen reduced hip fractures by 39% (HR 0.61 to 95% CI 0.41 to 0.91). This was consistent with estrogen's well-known effect on bone density and matched results from the combined arm.

Summary Results Table

| Outcome | Hazard Ratio | 95% CI | Direction | |---|---|---|---| | CHD (primary) | 0.91 | 0.75, 1.12 | Neutral | | Invasive breast cancer | 0.77 | 0.59, 1.01 | Reduced (borderline) | | Stroke | 1.39 | 1.10, 1.77 | Increased | | Pulmonary embolism | 1.34 | 0.87, 2.06 | Neutral | | Hip fracture | 0.61 | 0.41, 0.91 | Reduced | | Total mortality | 1.04 | 0.88, 1.22 | Neutral | | Global index | 1.01 | 0.91, 1.12 | Neutral |

Age-Stratified Findings

The most clinically relevant secondary analysis split results by age at enrollment. Women aged 50 to 59 showed the most favorable profile:

| Outcome (age 50, 59) | Hazard Ratio | 95% CI | |---|---|---| | CHD | 0.63 | 0.36, 1.08 | | Total mortality | 0.73 | 0.49, 1.07 | | Global index | 0.88 | 0.70, 1.11 |

While none of these reached conventional statistical significance in the original publication, the trend was consistent. A 2007 reanalysis in JAMA confirmed that women closer to menopause at initiation derived the most cardiovascular benefit, supporting what has become known as the "timing hypothesis."

Why the Trial Was Stopped Early

The NIH halted the trial in February 2004, roughly one year ahead of schedule. The stated reason was an increased stroke risk combined with a global index that was unlikely to show overall benefit even if the trial continued to completion. The decision was not driven by breast cancer or heart disease findings. Both of those outcomes were tracking neutral or favorable.

Early termination carries a cost. It limited the statistical power to detect modest benefits in younger subgroups and truncated follow-up for cancer outcomes that can take a decade or longer to manifest.

Honest Limitations

This trial had real methodological constraints that affect how results should be interpreted.

Age of participants. The average enrollee was 63. Most women starting HRT do so in their early 50s. Testing the drug in an older population makes it harder to detect benefits that depend on starting estrogen near menopause.

Single dose tested. Only 0.625 mg of CEE was studied. Lower doses, transdermal estradiol, and other formulations were not examined. The stroke risk seen here may not apply to transdermal routes, which bypass first-pass hepatic metabolism and have less impact on clotting factors.

Adherence attrition. With nearly half the treatment group off study pills by year six, intention-to-treat analyses underestimate the true biologic effect of sustained estrogen use.

Population characteristics. The cohort was predominantly white, mostly overweight or obese, and included many women with preexisting cardiovascular risk factors. Results may not generalize cleanly to healthier or more diverse populations.

No symptom-driven enrollment. Unlike most clinical HRT use, participants were not required to have menopausal symptoms. Women with hot flashes were already being treated with hormones, making them less likely to join a placebo-controlled trial. This may have selected for women whose biology responded differently to estrogen.

What It Means for Practice Today

The WHI estrogen-alone trial changed several clinical assumptions.

First, it showed that the risks attributed to "HRT" after the combined-arm results were largely driven by the progestin component, not estrogen itself. The Endocrine Society's 2015 guidelines and the 2022 North American Menopause Society position statement both acknowledge this distinction. Women with prior hysterectomy who are appropriate candidates for hormone therapy can use estrogen alone with a meaningfully different risk profile than combined HRT.

Second, the age-stratified data contributed to the timing hypothesis: estrogen started within 10 years of menopause, or before age 60, appears to carry less cardiovascular risk and possibly some cardioprotective benefit. This has influenced how clinicians counsel patients about the window of opportunity for initiating therapy.

Third, the breast cancer finding was unexpected and clinically important. Estrogen alone did not raise breast cancer risk, and extended follow-up showed a significant reduction. This runs counter to the public narrative that conflated all forms of hormone therapy with cancer risk.

The trial did not prove estrogen is universally safe. Stroke risk was real, and the benefit-risk calculus depends on the individual patient's age, years since menopause, body weight, stroke risk factors, and reason for considering therapy. But it did prove that estrogen alone is a different drug, with a different evidence base, than estrogen plus progestin.

Frequently asked questions

›

References

Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712. PubMed
LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305(13):1305-1314. PubMed
Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012;13(5):476-486. PubMed
Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-1477. PubMed
Premarin (conjugated estrogens) prescribing information. FDA. AccessData
The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. PubMed